ArticleJournal of hepatocellular carcinoma2023

Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.

Xuegang Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.